The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Large Volume Wearable Injectors Market (5th Edition), 2020-2030: Focus on Bolus, Basal and Continuous Delivery Devices

  • Lowest Price Guaranteed From USD 4,899

  • Published
    May 2020

  • Pages
    550

  • View Count
    6417

Example Insights

Large-Volume-Wearable-Injectors-Market-Context Large-Volume-Wearable-Injectors-Market-Word- cloud-analysis Large-Volume-Wearable-Injectors-Market-List-of-injectors Large-Volume-Wearable-Injectors-Market-Different-drug-storage-capacities
Large-Volume-Wearable-Injectors-Market-Pipeline Large-Volume-Wearable-Injectors-Market-Insulin-delivery Large-Volume-Wearable-Injectors-Market-Product-competitiveness-analysis Large-Volume-Wearable-Injectors-Market-Potential-acquisition-Targets
Large-Volume-Wearable-Injectors-Market-Geographical-distribution Large-Volume-Wearable-Injectors-Market-Patent-analysis Large-Volume-Wearable-Injectors-Market-Partnerships-and-collaborations Large-Volume-Wearable-Injectors-Market-Market-forecast
Large-Volume-Wearable-Injectors-Market-Futuer-forecast

 

Overview

Chronic diseases, such as diabetes, cardiovascular disorders, neurological disorders, autoimmune disorders and various types of cancer, are known to be the leading causes of death and disability across the world. The clinical conditions associated with these diseases affect patients’ overall quality of life. In fact, according to the World Health Organization (WHO), over 50% of the global population is currently estimated to be suffering from at least one chronic disease. The past few years have witnessed introduction of several innovative pharmaceutical interventions for the treatment of a number of such diseases. However, majority of the available treatment options require parenteral administration of the drug, frequent dosing, and involve repeated hospital visits. Treatment administration via the parenteral route is also associated with various concerns, such as dosing errors, risk of microbial contamination and needlestick injuries. These are known to be the primary factors affecting medication adherence and, thereby, have a significant impact on therapeutic outcomes. Over the past few years, a number of companies have developed advanced therapeutic delivery solutions (such as autoinjectors, pen injectors, prefilled syringes) to overcome the challenges associated with the administration of both conventional and novel drug / therapy molecules. In fact, these drug delivery devices can prove to be potential vehicles for drug administration in disease outbreaks / pandemics (such as the one being faced due to the novel corona virus / COVID-19). Amongst modern drug delivery practices, the concept of self-injection has facilitated the administration of medications outside the clinical setting. Such practices also allow reductions in healthcare costs and enable the optimal usage of healthcare resources. 

Specifically, large volume wearable injectors used for subcutaneous drug delivery, have become a preferred choice for administration of drugs in the home-care setting. Variants of these wearable devices have been designed to administer highly viscous drugs (such as biologics) in large volumes (more than 1 mL), offering numerous dosing options (basal, bolus or continuous), integrated safety mechanisms, and an almost negligible risk of needlestick injuries. Such devices have captured the interest of several stakeholders in this industry and are being used for the administration of both insulin and non-insulin drugs. The field is presently witnessing a lot of innovation, such as the development of integrated mobile applications with smart health monitoring, artificial intelligence algorithms and other interesting features (including provisions for reminders, and the ability to connect to web-based portals for sharing medical data with the concerned healthcare providers), visual / audible drug delivery confirmation notifications, automatic drug reconstitution, and error alerts. We believe that such efforts are likely to drive growth in this market over the coming years.

Scope of the Report

The “Large Volume Wearable Injectors Market (5th Edition), 2020-2030: Focus on Bolus , Basal and Continuous Delivery Devices” report features an extensive study of the current market landscape and the likely future evolution of these self-injection devices, over the next ten years. It specifically lays emphasis on the emergence of patient-centric, convenient, cost-effective and user-friendly wearable drug delivery solutions that are capable of administering large volumes of a drug subcutaneously, in the home-care setting. Amongst other elements, the report includes:

  • An overview of current market landscape of the large volume wearable injectors available for delivery of insulin and non-insulin drugs, providing information on status of development and device specifications, such as type of device (patch pump / injector and infusion pump / injector), type of dose administered (basal, bolus and others), route of administration (subcutaneous and others), mode of injection (needle, needle / cannula and needle / catheter), storage capacity of the device, actuation mechanism (electromechanical, rotary pump, cell / expanded battery, pressurized gas, osmotic pressure and others), usability (disposable and reusable), availability of prefilled drug reservoir and availability of device connectivity. The report also features additional information on availability of prefilled insulin cartridges, availability of continuous glucose monitoring / blood glucose monitoring (CGM / BGM) systems, availability of Automated Insulin Delivery feature and type of remote control features (control within device / personal diabetes manager (PDM) / smartphone) in the insulin delivery devices.  
  • A detailed competitiveness analysis of large volume wearable injectors based on various relevant parameters, such as supplier power (based on the experience / expertise of the developer) and product specifications (type of device, type of dose, storage capacity of the device, usability, route of administration, connectivity and availability of a continuous glucose monitoring / blood glucose monitoring (CGM / BGM) systems (in case of insulin devices). 
  • Elaborate profiles of the prominent companies that develop large volume wearable injectors. Each company profile features a brief overview of the company, its financial information (if available), information on its product portfolio, recent developments and an informed future outlook. Additionally, the report includes tabulated profiles of wearable drug device combination products.
  • An analysis of the partnerships that have been inked by the stakeholders in this domain, during the period between 2015 and 2020, covering acquisitions, product development agreements, product integration agreements, technology integration agreements, distribution and supply agreements, commercialization agreements, clinical trial agreements, licensing agreements, manufacturing agreements,  service agreements, and other relevant types of deals.
  • A detailed analysis on acquisition targets, taking into consideration the historical trend of the activity of the companies that have acquired other firms since 2000, and offering a means for other industry stakeholders to identify potential acquisition targets.
  • An in-depth analysis of the various patents that have been submitted / filed related to large volume wearable injectors over the last three decades. It also highlights the key parameters associated with the patents, including information on patent type, issuing authority / patent offices involved, Cooperative Patent Classification (CPC) symbols, emerging areas (in terms of number of patents filed / granted), company type and leading industry, non-industry and individual patent assignees (in terms of size of intellectual property portfolio).
  • A list of marketed drugs / therapies and pipeline candidates that are likely to be developed in combination with large volume wearable injectors in the near future, identified on the basis of an in-depth analysis of potential candidates, taking into consideration multiple parameters, such as stage of development, dosage, dose concentration, route of administration, type of dose and drug sales (in case of marketed drugs).
  • A social media analysis depicting prevalent and emerging trends, and the popularity of large volume wearable injectors, as observed on the social media platform, Twitter. The analysis was based on tweets posted on the platform in the last few years.
  • A detailed analysis of completed, ongoing and planned clinical trials of various large volume wearable injector products based on the various relevant parameters, such as trial registration year, current trial phase, trial status, study design, study focus, targeted therapeutic area and clinical outcomes.
  • A case study on the role of contract manufacturing organizations in the overall manufacturing process / supply chain of wearable injectors. It includes information on the services provided by contract service providers for manufacturing of various device components (primary containers), infusion sets, adhesives, closures and injection moldings. 
  • An elaborate discussion on the various guidelines established by major regulatory bodies for medical device approval across North America (the US, Canada and Mexico), Europe (the UK, France, Germany, Italy, Spain and rest of Europe), Asia-Pacific and rest of the world (Australia, Brazil, China, India, Israel, Japan, New Zealand, Singapore, South Africa, South Korea, Taiwan, and Thailand). The report also features an insightful multi-dimensional, heat map analysis, featuring a comparison of the contemporary regulatory and reimbursement scenarios in key geographies across the globe.

One of the key objectives of the report was to estimate the existing market size and potential future growth opportunities for large volume wearable injectors. Based on parameters, such as the number of commercialized devices, number of devices under development, price of the device and the annual adoption rate, we have provided an informed estimate on the likely evolution of the market over the period 2020-2030. The report also features sales forecasts for the overall large volume wearable injectors market with a detailed market segmentation on the [A] type of device (patch pump, injector and infusion pump and injector), [B] usability (reusable and disposable), [C] therapeutic area (neurological disorders, cardiovascular disorders, infectious disease, oncological disorders and others) and [D] key geographies (North America, Europe, Asia Pacific and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios namely the conservative, base and optimistic scenarios, which represent different tracks of the industry’s evolution. 

The opinions and insights presented in this study were influenced by discussions conducted with several stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals:

  • Mark Banister (CEO, Medipacs / RxActuator)
  • Michael Hooven (CEO, Enable Injections)
  • Jesper Roested (CEO, Subcuject)
  • Pieter Muntendam (former President and CEO, scPharmaceuticals)
  • Menachem Zucker (VP and Chief Scientist, Elcam Medical)
  • Graham Reynolds (VP and GM, Biologics, West Pharmaceutical Services)
  • Mindy Katz (Director of Product, Sorrel Medical)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the leading large volume wearable device developers? 
  • What are the prevalent trends within competitive landscape of large volume wearable injectors for delivery of non-insulin drugs?
  • What are the prevalent trends within competitive landscape of large volume wearable injectors for delivery of insulin?
  • What are the types of drug candidates that are suited for delivery via large volume wearable injectors?
  • Who are the key contract service providers involved in this domain?
  • What are medical device regulations across different regions?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Contents

Chapter Outlines

Chapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view on the current state of the large volume wearable injectors market in the short-mid-term and long term.

Chapter 3 provides a general introduction to large volume wearable injectors, highlighting the growing demand for medical devices that enable self-administration. The chapter lays emphasis on the need for such devices, in terms of the rising incidence and prevalence of chronic diseases. Additionally, it provides an overview of the different types of self-injection devices available in the market, listing their various advantages. It also features a brief discussion on the concerns related to the use of such devices.

Chapter 4 presents information on the large volume wearable injectors that are capable of delivering drugs and drug device combinations designed for delivery of specific drugs. In addition, the chapter includes a detailed analysis of these injector devices based on the status of development, type of device (patch pump / injector and infusion pump / injector), type of dose administered (basal, bolus and others), route of administration (subcutaneous and others), mode of injection (needle, needle / cannula and needle / catheter), storage capacity of the device,  actuation mechanism (electromechanical, rotary pump, cell / expanded battery, pressurized gas, osmotic pressure and others), usability (disposable and reusable), availability of prefilled drug reservoir and availability of device connectivity. In addition, the chapter provides a list of the large volume wearable injectors for delivery of insulin, along with the information on the aforementioned parameters and availability of prefilled insulin cartridges, availability of CGM / BGM systems, availability of Automated Insulin Delivery Feature and type of remote control features (control within device / PDM / smartphone).

Chapter 5 presents a detailed competitiveness analysis of large volume wearable injectors based on the supplier power and key product specifications. The analysis was designed to enable stakeholder companies to compare their existing capabilities within and beyond their respective peer groups and identify opportunities to achieve a competitive edge in the industry.

Chapter 6 provides detailed profiles of the key players that develop large volume wearable injectors. Each profile presents a brief overview of the company, financial information (if available), product portfolio, recent developments and an informed future outlook.

Chapter 7 provides tabulated profiles of drug device combination products. Each profile includes drug specifications, mechanism of action, current status of development, dosage and sales information.

Chapter 8 features an in-depth analysis and discussion on the various partnerships inked between the players in this market in the time period between 2015 and 2020, covering acquisitions, product development agreements, product integration agreements, technology integration agreements, distribution and supply agreements, commercialization agreements, clinical trial agreements, licensing agreements, manufacturing agreements,  service agreements, and other relevant types of deals.

Chapter 9 provides a detailed acquisition target analysis, taking into consideration the historical trend of the activity of the companies that have acquired other firms since 2015, and offering a means for other industry stakeholders to identify potential acquisition targets.

Chapter 10 provides an in-depth patent analysis, presenting an overview of the filed / granted patents related to wearable injectors for the delivery of drugs in large volumes. For this analysis, we looked at the patents that have been published by various players over the last three decades. The analysis highlights the key information and trends associated with these patents, including patent type (granted patents, patent applications and others), patent publication year, issuing authority / patent offices involved, CPC symbols, emerging focus areas, type of players (industry and non-industry players) and the leading industry players, non-industry players and individual patent assignees. The chapter also includes a patent benchmarking analysis and patent valuation analysis.

Chapter 11 presents a list of marketed and pipeline molecules that are likely to be considered for delivery via large volume wearable injectors in the future, identified on the basis of an analysis of the potential candidates, taking into consideration the various parameters, such as stage of development, dosage, dose concentration, route of administration, type of dose and drug sales (in case of marketed drugs). For the purpose of this analysis, we collated a list of over 100 top-selling marketed drugs, which were initially screened on the basis of route of administration (subcutaneous / intramuscular / intravenous). Additionally, we compiled a list of pipeline molecules that are being investigated for delivery via the aforementioned routes. The likelihood of delivery via a large volume wearable injector in the future was estimated using the weighted average method.

Chapter 12 provides insights on the popularity of large volume wearable injectors on the social media platform, Twitter. The chapter highlights the yearly distribution of tweets posted on the platform and the most significant events responsible for increase in the volume of tweets each year. Additionally, the chapter showcases the most frequently mentioned keywords / phrases and social media activity of the most popular players with the comparison of the tweets associated with their product. It also presents a bubble analysis of the most influential authors related to large volume wearable injectors on Twitter.

Chapter 13 presents a comprehensive clinical trial analysis of the complete and active studies being conducted to evaluate the combinations of drugs and large volume wearable injectors based on the various parameters, such as trial registration year, current trial phase, current trial status, study design, study focus, targeted therapeutic area and clinical endpoints. 

Chapter 14 includes a brief case study on the role of contract manufacturing organizations in the overall manufacturing process / supply chain of a wearable injector. It includes information on the services provided by such organizations for manufacturing of device components (primary containers), infusion sets, adhesives, closures and injection moldings. In addition, it includes a schematic world map representation highlighting the location of the CMOs and their device manufacturing service portfolio.

Chapter 15 features a discussion on the various guidelines established by major regulatory bodies for medical device approvals across North America (the US, Canada and Mexico), Europe (the UK, France, Germany, Italy, Spain and rest of Europe), Asia-Pacific and rest of the world (Australia, Brazil, China, India, Israel, Japan, New Zealand, Singapore, South Africa, South Korea, Taiwan, and Thailand). The report also features an insightful multi-dimensional heat map analysis, featuring a comparison of the contemporary regulatory and reimbursement scenarios in key geographies across the globe.  

Chapter 16 presents an insightful market forecast analysis, highlighting the future potential of large volume wearable injectors (for delivery of non-insulin drugs) till the year 2030. We have segregated the opportunity on the basis of the type of device (patch pump, injector and infusion pump and injector), usability (reusable and disposable), key therapeutic areas (neurological disorders, cardiovascular disorders, infectious disease, oncological disorders and others) and key geographies (North America, Europe, Asia Pacific and rest of the world). In addition, the chapter presents an opportunity analysis of the market for large volume wearable injectors for delivery of insulin, till the year 2030.

Chapter 17 presents a detailed discussion on the future opportunities of wearable injectors for large volume drug delivery. It also highlights the key parameters and trends that are likely to influence the future of this market, under a detailed SWOT framework.

Chapter 18 is a collection of interview transcripts of the discussions held with key stakeholders in this market. In this chapter, we have presented the details of interviews held with Mark Banister (CEO, Medipacs), Michael Hooven (CEO, Enable Injections), Jesper Roested (CEO, Subcuject), Pieter Muntendam (former President and CEO, scPharmaceuticals), Menachem Zucker (VP and Chief Scientist, Elcam Medical), Graham Reynolds (VP and GM, Biologics, West Pharmaceutical Services) and Mindy Katz (Director of Product, Sorrel Medical)

Chapter 19 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 20 is an appendix, which contains a list of companies and organizations mentioned in this report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. An Overview of Drug Delivery Devices
3.3. Conventional Parenteral Drug Delivery 
3.3.1 Needlestick Injuries
3.3.1.1. Incidence and Cost Burden
3.3.1.2. Prevention of Needlestick Injuries
3.3.1.3. Government Legislations for the Prevention of Needlestick Injuries

3.4. Emergence of Self-Administration Devices
3.4.1. Driving Factors
3.4.1.1. Rising Burden of Chronic Diseases
3.4.1.2. Healthcare Cost Savings
3.4.1.3. Need for Immediate Treatment in Emergency Situations
3.4.1.4. Growing Injectable Drugs Market
3.4.1.5. Rising Focus on Patient Centricity
3.4.1.6. Need for Improving Medication Adherence

3.5. Available Self-Injection Devices
3.5.1. Prefilled Syringes
3.5.2. Pen-Injectors
3.5.3. Autoinjectors
3.5.4. Needle-Free Injectors
3.5.5. Large Volume Wearable Injectors

3.6. Regulatory Considerations
3.6.1. Medical Devices
3.6.2. Drug Device Combinations

3.7. Future Perspectives

4. LARGE VOLUME WEARABLE INJECTORS: CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Large Volume Wearable Injectors: Overall Market Landscape
4.2.1. Large Volume Wearable Injectors for Non-Insulin Drugs: Market Landscape
4.2.1.1. Analysis by Stage of Development
4.2.1.2. Analysis by Type of Device
4.2.1.3. Analysis by Type of Dose
4.2.1.4. Analysis by Route of Administration
4.2.1.5. Analysis by Mode of Injection
4.2.1.6. Analysis by Volume / Storage Capacity
4.2.1.7. Analysis by Actuation Mechanism
4.2.1.8. Analysis by Usability
4.2.1.9. Analysis by Availability of Prefilled Drug Reservoir
4.2.1.10. Analysis by Availability of Connectivity

4.2.2. Large Volume Drug Device Combinations: Market Landscape
4.2.2.1. Analysis by Stage of Development
4.2.2.2. Analysis by Type of Device
4.2.2.3. Analysis by Drug Compatibility
4.2.2.4. Analysis by Type of Dose
4.2.2.5. Analysis by Route of Administration
4.2.2.6. Analysis by Mode of Injection
4.2.2.7. Analysis by Therapeutic Area
4.2.2.8. Analysis by Volume / Storage Capacity
4.2.2.9. Analysis by Usability

4.2.3. Large Volume Wearable Injectors for Non-Insulin Drugs: Analysis of Developers (Devices and Drug Device Combinations)
4.2.3.1. Analysis by Year of Establishment
4.2.3.2. Analysis by Company Size
4.2.3.3. Analysis by Geography

4.2.4. Large Volume Wearable Injectors for Insulin: Market Landscape
4.2.4.1. Analysis by Stage of Development
4.2.4.2. Analysis by Type of Device
4.2.4.3. Analysis by Volume / Storage Capacity
4.2.4.4. Analysis by Usability
4.2.4.5. Analysis by Availability of Prefilled Insulin Cartridges
4.2.4.6. Analysis by Availability of CGM / BGM System
4.2.4.7. Analysis by Availability of Automated Insulin Delivery (AID) Feature
4.2.4.8. Analysis by Availability of Connectivity
4.2.4.9. Analysis by Type of Remote Control Features

4.2.5. Large Volume Wearable Injectors for Insulin: Analysis of Developers
4.2.5.1. Analysis by Year of Establishment
4.2.5.2. Analysis by Company Size
4.2.5.3. Analysis by Geography

5. PRODUCT COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Methodology
5.3. Product Competitiveness Analysis
5.3.1. Large Volume Wearable Injectors for Non-Insulin Drugs
5.3.2. Large Volume Drug Device Combinations
5.3.3. Large Volume Wearable Injectors for Insulin

6. LARGE VOLUME WEARABLE INJECTORS: KEY PLAYERS
6.1. Chapter Overview
6.2. Large Volume Wearable Injectors for Non-Insulin Drugs: Key Players
6.2.1. Becton Dickinson
6.2.1.1. Company Snapshot
6.2.1.2. Product Portfolio
6.2.1.3. Financial Information
6.2.1.4. Recent Developments and Future Outlook

6.2.2. Bespak
6.2.2.1. Company Snapshot
6.2.2.2. Product Portfolio
6.2.2.3. Financial Information
6.2.2.4. Recent Developments and Future Outlook

6.2.3. Enable Injections
6.2.3.1. Company Snapshot
6.2.3.2. Product Portfolio
6.2.3.3. Recent Developments and Future Outlook

6.2.4. Insulet
6.2.4.1. Company Snapshot
6.2.4.2. Product Portfolio
6.2.4.3. Financial Information
6.2.4.4. Recent Developments and Future Outlook

6.2.5. Roche
6.2.5.1. Company Snapshot
6.2.5.2. Product Portfolio
6.2.5.3. Financial Information
6.2.5.4. Recent Developments and Future Outlook

6.2.6. Sensile Medical
6.2.6.1. Company Snapshot
6.2.6.2. Product Portfolio
6.2.6.3. Recent Developments and Future Outlook

6.2.7. Sonceboz
6.2.7.1. Company Snapshot
6.2.7.2. Product Portfolio
6.2.7.3. Recent Developments and Future Outlook

6.2.8. SteadyMed Therapeutics
6.2.8.1. Company Snapshot
6.2.8.2. Product Portfolio
6.2.8.3. Recent Developments and Future Outlook

6.2.9. Weibel CDS
6.2.9.1. Company Snapshot
6.2.9.2. Product Portfolio
6.2.9.3. Recent Developments and Future Outlook

6.2.10. West Pharmaceutical Services
6.2.10.1. Company Snapshot
6.2.10.2. Product Portfolio
6.2.10.3. Financial Information
6.2.10.4. Recent Developments and Future Outlook

6.3. Large Volume Wearable Injectors for Insulin: Key Players

6.3.1. CeQur
6.3.1.1. Company Snapshot
6.3.1.2. Product Portfolio
6.3.1.3. Recent Developments and Future Outlook

6.3.2. Debiotech
6.3.2.1. Company Snapshot
6.3.2.2. Product Portfolio
6.3.2.3. Recent Developments and Future Outlook

6.3.3. Eli Lilly
6.3.3.1. Company Snapshot
6.3.3.2. Product Portfolio
6.3.3.3. Financial Information
6.3.3.4. Recent Developments and Future Outlook

6.3.4. Medtronic
6.3.4.1. Company Snapshot
6.3.4.2. Product Portfolio
6.3.4.3. Financial Information
6.3.4.4. Recent Developments and Future Outlook

6.3.5. PharmaSens
6.3.5.1. Company Snapshot
6.3.5.2. Product Portfolio
6.3.5.3. Recent Developments and Future Outlook

6.3.6. SOOIL Development
6.3.6.1. Company Snapshot
6.3.6.2. Product Portfolio
6.3.6.3. Recent Developments and Future Outlook

6.3.7. Tandem Diabetes Care
6.3.7.1. Company Snapshot
6.3.7.2. Product Portfolio
6.3.7.3. Financial Information
6.3.7.4. Recent Developments and Future Outlook

7. DRUG-DEVICE COMBINATIONS: TABULATED PROFILES
7.1. Chapter Overview
7.2. Apomorphine / D-mine® Pump
7.3. Apomorphine / ND0701
7.4. Bupivacaine / SMT-301
7.5. Ceftriaxone / sc2Wear® Infusor
7.6. Furosemide / 3 mL Micropump
7.7. Furosemide / FUROSCIX® On-body Infusor
7.8. Herceptin® / Single Use Injector
7.9. Ketorolac / SMT-201
7.10. Levodopa and Carbidopa / ND0612 and ND0901
7.11. Lutrepulse / The LUTREPULSE® System
7.12. Repatha® / Pushtronex® System
7.13. Treprostinil / Trevyent®

8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Large Volume Wearable Injectors: List of Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Year of Partnership and Type of Partner
8.3.4. Analysis by Type of Partnership and Type of Partner
8.3.5. Most Active Players: Analysis by Number of Partnerships
8.3.6. Regional Analysis
8.3.7. Intercontinental and Intracontinental Agreements

9. KEY ACQUISITION TARGETS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Scoring Criteria and Key Assumptions
9.4. Potential Strategic Acquisition Targets for Non-Insulin Drug Delivery Players
9.5. Potential Strategic Acquisition Targets for Insulin Drug Delivery Players
9.6. Concluding Remarks

10. PATENT ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Large Volume Wearable Injectors: Patent Analysis
10.3.1. Analysis by Publication Year
10.3.2. Analysis by Issuing Authority / Patent Offices Involved
10.3.3. Analysis by CPC Symbols
10.3.4. Emerging Focus Areas
10.3.5. Analysis by Type of Industry
10.3.6. Leading Players: Analysis by Number of Patents

10.4. Large Volume Wearable Injectors: Patent Benchmarking Analysis
10.4.1. Analysis by Patent Characteristics

10.5. Large Volume Wearable Injectors: Patent Valuation Analysis

11. LARGE VOLUME WEARABLE INJECTORS: LIKELY DRUG CANDIDATES
11.1. Chapter Overview
11.2. Marketed Drugs
11.2.1. Most Likely Candidates for Delivery via Large Volume Wearable Injectors
11.2.2. Likely Candidates for Delivery via Large Volume Wearable Injectors
11.2.3. Less Likely Candidates for Delivery via Large Volume Wearable Injectors
11.2.4. Unlikely Candidates for Delivery via Large Volume Wearable Injectors

11.3. Clinical Drug Candidates
11.3.1. Biologics
11.3.1.1. Most Likely Candidates for Delivery via Large Volume Wearable Injectors
11.3.1.2. Likely Candidates for Delivery via Large Volume Wearable Injectors
11.3.1.3. Less Likely Candidates for Delivery via Large Volume Wearable Injectors
11.3.1.4. Unlikely Candidates for Delivery via Large Volume Wearable Injectors

11.3.2. Small Molecules
11.3.2.1. Most Likely Candidates for Delivery via Large Volume Wearable Injectors
11.3.2.2. Likely Candidates for Delivery via Large Volume Wearable Injectors
11.3.2.3. Less Likely Candidates for Delivery via Large Volume Wearable Injectors
11.3.2.4. Unlikely Candidates for Delivery via Large Volume Wearable Injectors

12. EMERGING TRENDS ON SOCIAL MEDIA
12.1. Chapter Overview
12.2. Large Volume Wearable Injectors: Trends on Twitter
12.2.1. Historical Trend in Volume of Tweets
12.2.2. Trending Words / Phrases Related to Large Volume Wearable Injectors
12.2.3. Most Influential Authors

12.2.4. Popular Players on Twitter
12.2.4.1. Roche (Accu-Chek® Solo Micropump System)
12.2.4.2. Insulet (Omnipod®)
12.2.4.3. Medtronic (MiniMed® Wearable Injectors)
12.2.4.4. Comparison of Popular Players Based on Number of Tweets

12.3. Concluding Remarks

13.CLINICAL TRIAL ANALYSIS
13.1. Chapter Overview
13.2. Scope and Methodology
13.3. Large Volume Wearable Injectors: Clinical Trial Analysis
13.3.1. Analysis by Trial Registration Year
13.3.2. Analysis by Trial Phase
13.3.3. Analysis by Trial Status
13.3.4. Analysis by Study Design
13.3.5. Analysis by Study Focus
13.3.6. Analysis by Target Therapeutic Area
13.3.7. Analysis by Clinical Endpoints

14. CASE STUDY: ROLE OF CMOs IN DEVICE DEVELOPMENT SUPPLY CHAIN
14.1. Chapter Overview
14.2. Device Development Supply Chain
14.3. Significance of CMOs in the Drug Delivery Device Development Process
14.4. List of Contract Manufacturing Organizations
14.4.1. Contract Manufacturers: Geographical Distribution and Services Offered

15. REGULATORY AND REIMBURSEMENT LANDSCAPE FOR MEDICAL DEVICES
15.1. Chapter Overview
15.2. General Regulatory and Reimbursement Guidelines for Medical Devices

15.3. Regulatory and Reimbursement Landscape in North America
15.3.1. The US Scenario
15.3.1.1. Regulatory Authority
15.3.1.2. Review / Approval Process
15.3.1.3. Reimbursement Landscape
15.3.1.3.1. Payer Mix
15.3.1.3.2. Reimbursement Process
15.3.2. The Canadian Scenario
15.3.2.1. Regulatory Authority
15.3.2.2. Review / Approval Process
15.3.2.3. Reimbursement Landscape
15.3.2.3.1. Payer Mix
15.3.2.3.2. Reimbursement Process
15.3.3. The Mexican Scenario
15.3.3.1. Regulatory Authority
15.3.3.2. Review / Approval Process
15.3.3.3. Reimbursement Landscape
15.3.3.3.1. Payer Mix

15.4. Regulatory and Reimbursement Landscape in Europe
15.4.1. Overall Scenario
15.4.1.1. Overall Regulatory Authority
15.4.1.2. Overall Review / Approval Process
15.4.2. The UK Scenario
15.4.2.1. Regulatory Authority
15.4.2.2. Review / Approval Process
15.4.2.3. Reimbursement Landscape
15.4.2.3.1. Payer Mix
15.4.2.3.2. Reimbursement Process

15.4.3. The French Scenario
15.4.3.1. Regulatory Authority
15.4.3.2. Review / Approval Process
15.4.3.3. Reimbursement Landscape
15.4.3.3.1. Payer Mix
15.4.3.3.2. Reimbursement Process

15.4.4. The German Scenario
15.4.4.1. Regulatory Authority
15.4.4.2. Review / Approval Process
15.4.4.3. Reimbursement Landscape
15.4.4.3.1. Payer Mix
15.4.4.3.2. Reimbursement Process

15.4.5. The Italian Scenario
15.4.5.1. Regulatory Authority
15.4.5.2. Review / Approval Process
15.4.5.3. Reimbursement Landscape
15.4.5.3.1. Payer Mix
15.4.5.3.2. Reimbursement Process

15.4.6. The Spanish Scenario
15.4.6.1. Regulatory Authority
15.4.6.2. Review / Approval Process
15.4.6.3. Reimbursement Landscape
15.4.6.3.1. Payer Mix
15.4.6.3.2. Reimbursement Process

15.5. Regulatory and Reimbursement Landscape in Asia-Pacific and Rest of the World
15.5.1. The Australian Scenario
15.5.1.1. Regulatory Authority
15.5.1.2. Review / Approval Process
15.5.1.3. Reimbursement Landscape
15.5.1.3.1. Payer Mix
15.5.1.3.2. Reimbursement Process

15.5.2. The Brazilian Scenario
15.5.2.1. Regulatory Authority
15.5.2.2. Review / Approval Process
15.5.2.3. Reimbursement Landscape
15.5.2.3.1. Payer Mix
15.5.2.3.2. Reimbursement Process

15.5.3. The Chinese Scenario
15.5.3.1. Regulatory Authority
15.5.3.2. Review / Approval Process
15.5.3.3. Reimbursement Landscape
15.5.3.3.1. Payer Mix
15.5.3.3.2. Reimbursement Process

15.5.4. The Indian Scenario
15.5.4.1. Regulatory Authority
15.5.4.2. Review / Approval Process
15.5.4.3. Reimbursement Landscape
15.5.4.3.1. Payer Mix

15.5.5. The Israeli Scenario
15.5.5.1. Regulatory Authority
15.5.5.2. Review / Approval Process
15.5.5.3. Reimbursement Landscape
15.5.5.3.1. Payer Mix

15.5.6. The Japanese Scenario
15.5.6.1. Regulatory Authority
15.5.6.2. Review / Approval Process
15.5.6.3. Reimbursement Landscape
15.5.6.3.1. Payer Mix
15.5.6.3.2. Reimbursement Process

15.5.7. The New Zealand Scenario
15.5.7.1. Regulatory Authority
15.5.7.2. Review / Approval Process
15.5.7.3. Reimbursement Landscape
15.5.7.3.1. Payer Mix
15.5.7.3.2. Reimbursement Process

15.5.8. The Singaporean Scenario
15.5.8.1. Regulatory Authority
15.5.8.2. Review / Approval Process
15.5.8.3. Reimbursement Landscape
15.5.8.3.1. Payer Mix
15.5.8.3.2. Reimbursement Process

15.5.9. The South Korea Scenario
15.5.9.1. Regulatory Authority
15.5.9.2. Review / Approval Process
15.5.9.3. Reimbursement Landscape
15.5.9.3.1. Payer Mix
15.5.9.3.2. Reimbursement Process

15.5.10. The South African Scenario
15.5.10.1. Regulatory Authority
15.5.10.2. Review / Approval Process
15.5.10.3. Reimbursement Landscape

15.5.11. The Taiwanese Scenario
15.5.11.1. Regulatory Authority
15.5.11.2. Review / Approval Process
15.5.11.3. Reimbursement Landscape
15.5.11.3.1. Payer Mix
15.5.11.3.2. Reimbursement Process

15.5.12. The Thailand Scenario
15.5.12.1. Regulatory Authority
15.5.12.2. Review / Approval Process
15.5.12.3. Reimbursement Landscape

15.6. Comparison of Regional Regulatory Environment
15.7. Concluding Remarks

16. MARKET SIZING AND OPPORTUNITY ANALYSIS
16.1. Chapter Overview
16.2. Forecast Methodology and Key Assumptions
16.3. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, 2020-2030 (By Value)
16.3.1. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device, 2020-2030 (By Value)
16.3.2 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability, 2020-2030 (By Value)
16.3.3 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area, 2020-2030 (By Value)

16.4 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, 2020-2030 (By Value)
16.4.1 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Type of Device, 2020-2030 (By Value)
16.4.2 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Usability, 2020-2030 (By Value)
16.4.3 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Therapeutic Area, 2020-2030 (By Value)

16.5 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, 2020-2030 (By Value)
16.5.1 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Type of Device, 2020-2030 (By Value)
16.5.2 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Usability, 2020-2030 (By Value)
16.5.3 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Therapeutic Area, 2020-2030 (By Value)

16.6 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific, 2020-2030 (By Value)
16.6.1 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Type of Device, 2020-2030 (By Value)
16.6.2 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Usability, 2020-2030 (By Value)
16.6.3 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Therapeutic Area, 2020-2030 (By Value)

16.7. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, 2020-2030 (By Volume)
16.7.1. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device, 2020-2030 (By Volume)
16.7.2 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability, 2020-2030 (By Volume)
16.7.3 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area, 2020-2030 (By Volume)

16.8 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, 2020-2030 (By Volume)
16.8.1 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Type of Device, 2020-2030 (By Volume)
16.8.2 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Usability, 2020-2030 (By Volume)
16.8.3 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Therapeutic Area, 2020-2030 (By Volume)

16.9 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, 2020-2030 (By Volume)
16.9.1 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Type of Device, 2020-2030 (By Volume)
16.9.2 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Usability, 2020-2030 (By Volume)
16.9.3 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Therapeutic Area, 2020-2030 (By Volume)

16.1 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific, 2020-2030 (By Value)
16.10.1 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Type of Device, 2020-2030 (By Value)
16.10.2 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Usability, 2020-2030 (By Value)
16.10.3 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Therapeutic Area, 2020-2030 (By Value)

16.11. Global Large Volume Wearable Injectors Market for Insulin, 2020-2030
16.11.1 Global Large Volume Wearable Injectors Market for Insulin: Distribution by Type of Device, 2020-2030
16.11.2 Global Large Volume Wearable Injectors Market for Insulin: Distribution by Usability, 2020-2030

16.12 Large Volume Wearable Injectors Market for Insulin in North America, 2020-2030
16.12.1 Large Volume Wearable Injectors Market for Insulin in North America: Distribution by Type of Device, 2020-2030
16.12.2 Large Volume Wearable Injectors Market for Insulin in North America: Distribution by Usability, 2020-2030

16.13 Large Volume Wearable Injectors Market for Insulin in Europe, 2020-2030
16.13.1 Large Volume Wearable Injectors Market for Insulin in Europe: Distribution by Type of Device, 2020-2030
16.13.2 Large Volume Wearable Injectors Market for Insulin in Europe: Distribution by Usability, 2020-2030

16.14 Large Volume Wearable Injectors Market for Insulin in Asia Pacific, 2020-2030
16.14.1 Large Volume Wearable Injectors Market for Insulin in Asia Pacific: Distribution by Type of Device, 2020-2030
16.14.2 Large Volume Wearable Injectors Market for Insulin in Asia Pacific: Distribution by Usability, 2020-2030

17. SWOT ANALYSIS
17.1. Chapter Overview
17.2. SWOT Analysis
17.2.1. Strengths
17.2.2. Weaknesses
17.2.3. Opportunities
17.2.4. Threats

17.3. Future Growth Opportunities

18. EXECUTIVE INSIGHTS
18.1. Chapter Overview
18.2. Medipacs
18.2.1. Company Snapshot
18.2.2. Interview Transcript: Mark Banister, Chief Executive Officer

18.3. Enable Injections
18.3.1. Company Snapshot
18.3.2. Interview Transcript: Michael Hooven, Chief Executive Officer

18.4. Subcuject
18.4.1. Company Snapshot
18.4.2. Interview Transcript: Jesper Roested, Chief Executive Officer

18.5. scPharmaceuticals
18.5.1. Company Snapshot
18.5.2. Interview Transcript: Pieter Muntendam, former President and Chief Executive Officer

18.6. Elcam Medical
18.6.1. Company Snapshot
18.6.2. Interview Transcript: Menachem Zucker, Vice President and Chief Scientist

18.7. West Pharmaceutical Services
18.7.1. Company Snapshot
18.7.2. Interview Transcript: Graham Reynolds, Vice President and General Manager, Biologics

18.8. Sorrel Medical
18.8.1. Company Snapshot
18.8.2. Interview Transcript: Mindy Katz, Director of Product

19. APPENDIX 1: TABULATED DATA

20. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Popular Drug Delivery Systems
Figure 3.2 Evolution of Healthcare Safety Legislations
Figure 3.3 Large Volume Wearable Injectors Market: Driving Factors
Figure 3.4 Types of Self-Injection Devices
Figure 4.1 Large Volume Wearable Injectors: Overall Market Landscape
Figure 4.2 Large Volume Wearable Injectors for Non-Insulin Drugs: Analysis by Stage of Development
Figure 4.3 Large Volume Wearable Injectors for Non-Insulin Drugs: Analysis by Type of Device
Figure 4.4 Large Volume Wearable Injectors for Non-Insulin Drugs: Analysis by Type of Dose
Figure 4.5 Large Volume Wearable Injectors for Non-Insulin Drugs: Analysis by Route of Administration
Figure 4.6 Large Volume Wearable Injectors for Non-Insulin Drugs: Analysis by Mode of Injection
Figure 4.7 Large Volume Wearable Injectors for Non-Insulin Drugs: Analysis by Volume / Storage Capacity
Figure 4.8 Large Volume Wearable Injectors for Non-Insulin Drugs: Analysis by Actuation Mechanism
Figure 4.9 Large Volume Wearable Injectors for Non-Insulin Drugs: Analysis by Usability
Figure 4.10 Large Volume Wearable Injectors for Non-Insulin Drugs: Analysis by Availability of Prefilled Drug Reservoir
Figure 4.11 Large Volume Wearable Injectors for Non-Insulin Drugs: Analysis by Connectivity
Figure 4.12 Large Volume Drug Device Combinations: Analysis by Stage of Development
Figure 4.13 Large Volume Drug Device Combinations: Analysis by Type of Device
Figure 4.14 Large Volume Drug Device Combinations: Analysis by Drug Compatibility
Figure 4.15 Large Volume Drug Device Combinations: Analysis by Type of Dose
Figure 4.16 Large Volume Drug Device Combinations: Analysis by Route of Administration
Figure 4.17 Large Volume Drug Device Combinations: Analysis by Mode of Injection
Figure 4.18 Large Volume Drug Device Combinations: Analysis by Therapeutic Area
Figure 4.19 Large Volume Drug Device Combinations: Analysis by Volume / Storage Capacity
Figure 4.20 Large Volume Drug Device Combinations: Analysis by Usability
Figure 4.21 Large Volume Wearable Injectors for Non-Insulin Drugs: Analysis of Developers by Year of Establishment (Devices and Drug Device Combinations)
Figure 4.22 Large Volume Wearable Injectors for Non-Insulin Drugs: Analysis of Developers by Size (Devices and Drug Device Combinations)
Figure 4.23 Large Volume Wearable Injectors for Non-Insulin Drugs: Analysis of Developers by Geography (Devices and Drug Device Combinations)
Figure 4.24 Large Volume Wearable Injectors for Insulin: Analysis by Stage of Development
Figure 4.25 Large Volume Wearable Injectors for Insulin: Analysis by Type of Device
Figure 4.26 Large Volume Wearable Injectors for Insulin: Analysis by Volume / Storage Capacity
Figure 4.27 Large Volume Wearable Injectors for Insulin: Analysis by Usability
Figure 4.28 Large Volume Wearable Injectors for Insulin: Analysis by Availability of Prefilled Insulin Cartridges
Figure 4.29 Large Volume Wearable Injectors for Insulin: Analysis by Availability of CGM / BGM System
Figure 4.30 Large Volume Wearable Injectors for Insulin: Analysis by Availability of Automated Insulin Delivery (AID) Feature
Figure 4.31 Large Volume Wearable Injectors for Insulin: Analysis by Availability of Connectivity
Figure 4.32 Large Volume Wearable Injectors for Insulin: Analysis by Type of Remote Control Features
Figure 4.33 Large Volume Wearable Injectors for Insulin: Analysis of Developers by Year of Establishment
Figure 4.34 Large Volume Wearable Injectors for Insulin: Analysis of Developers by Size
Figure 4.35 Large Volume Wearable Injectors for Insulin: Analysis of Developers by Geography
Figure 5.1 Product Competitiveness Analysis: Large Volume Wearable Injectors for Non-Insulin Drugs
Figure 5.2 Product Competitiveness Analysis: Large Volume Drug Device Combinations
Figure 5.3 Product Competitiveness Analysis: Large Volume Wearable Injectors for Insulin
Figure 8.1 Partnerships and Collaborations: Analysis by Year of Partnership
Figure 8.2 Partnerships and Collaborations: Analysis by Type of Partnership
Figure 8.3 Partnerships and Collaborations: Analysis by Year of Partnership and Type of Partner
Figure 8.4 Partnerships and Collaborations: Analysis by Type of Partnership and Type of Partner
Figure 8.5 Most Active Players: Analysis by Number of Partnerships
Figure 8.6 Partnerships and Collaborations: Regional Analysis
Figure 8.7 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 10.1 Patent Analysis: Distribution by Type of Patent
Figure 10.2 Patent Analysis: Distribution by Publication Year
Figure 10.3 Patent Analysis: Distribution by Issuing Authority / Patent Offices Involved
Figure 10.4 Patent Analysis: Distribution by CPC Symbols
Figure 10.5 Patent Analysis: Emerging Focus Areas
Figure 10.6 Patent Analysis: Cumulative Distribution by Type of Organization
Figure 10.7 Patent Analysis: Leading Industry Players
Figure 10.8 Patent Analysis: Leading Non-Industry Players
Figure 10.9 Patent Analysis: Leading Individual Assignees
Figure 10.10 Patent Analysis (Industry Players): Benchmarking by Patent Characteristics
Figure 10.11 Patent Analysis: Distribution of Patents by Age
Figure 10.12 Large Volume Wearable Injectors: Patent Valuation
Figure 12.1 Social Media Analysis: Historical Trend related to Large Volume Wearable Injectors on Twitter
Figure 12.2 Social Media Analysis: Trending Words / Phrases on Twitter
Figure 12.3 Social Media Analysis: Most Influential Authors on Twitter
Figure 12.4 Social Media Analysis: Comparison of Popular Players on Twitter
Figure 12.5 Social Media Activity of Roche
Figure 12.6 Social Media Activity of Insulet
Figure 12.7 Social Media Activity of Medtronic
Figure 13.1 Clinical Trial Analysis: Cumulative Distribution of Number of Trials by Start Year, 2010-2020
Figure 13.2 Clinical Trial Analysis: Distribution by Trial Registration Year
Figure 13.3 Clinical Trial Analysis: Distribution by Trial Phase
Figure 13.4 Clinical Trial Analysis: Distribution by Trial Status
Figure 13.5 Clinical Trial Analysis: Distribution by Study Design
Figure 13.6 Clinical Trial Analysis: Distribution by Study Focus
Figure 13.7 Clinical Trial Analysis: Distribution by Target Therapeutic Area
Figure 13.8 Clinical Trial Analysis: Distribution by Clinical Endpoints
Figure 14.1 CMOs for Large Volume Wearable Injectors: Market Landscape and Services Offered
Figure 15.1 Key Regulatory Authorities for Medical Devices
Figure 15.2 Medical Devices Review / Approval Process: US
Figure 15.3 Healthcare Insurance Coverage in the US: Distribution by Type of Coverage
Figure 15.4 Medical Devices National Coverage Determination Process: US
Figure 15.5 Medical Devices Review / Approval Process: Canada
Figure 15.6 Healthcare Insurance Coverage in Canada: Distribution by Type of Coverage
Figure 15.7 Medical Devices Review / Approval Process: Mexico
Figure 15.8 Regulatory Bodies in EU5 Countries
Figure 15.9 Steps involved in CE Marking Process
Figure 15.10 Medical Devices Review / Approval Process: Europe
Figure 15.11 Medical Devices Review / Approval Process: UK
Figure 15.12 Healthcare Insurance Coverage in the UK: Distribution by Type of Coverage
Figure 15.13 Medical Devices Reimbursement Process: UK
Figure 15.14 Healthcare Insurance Coverage in France: Distribution by Type of Coverage
Figure 15.15 Medical Devices Reimbursement Process: France
Figure 15.16 Healthcare Insurance Coverage in Germany: Distribution by Type of Coverage
Figure 15.17 Medical Devices Reimbursement Process for In-Patient Setting: Germany
Figure 15.18 Medical Devices Reimbursement Process for Out-Patient Care: Germany
Figure 15.19 Healthcare Insurance Coverage in Italy: Distribution by Type of Coverage
Figure 15.20 Medical Devices Reimbursement Process: Italy
Figure 15.21 Healthcare Insurance Coverage in Spain: Distribution by Type of Coverage
Figure 15.22 Medical Devices Reimbursement Process: Spain
Figure 15.23 Medical Devices Review / Approval Process: Australia
Figure 15.24 Healthcare Insurance Coverage in Australia: Percentage Distribution by Type of Coverage
Figure 15.25 Medical Devices Review / Approval Process: Brazil
Figure 15.26 Medical Devices Reimbursement Process: Brazil
Figure 15.27 Medical Devices Review / Approval Process: China
Figure 15.28 Healthcare Insurance Coverage in China: Percentage Distribution by Type of Coverage
Figure 15.29 Medical Devices Reimbursement Process: Shanghai
Figure 15.30 Medical Devices Review / Approval Process: India
Figure 15.31 Healthcare Insurance Coverage in Israel: Percentage Distribution by Type of Coverage
Figure 15.32 Medical Devices Review / Approval Process: Japan
Figure 15.33 Medical Devices Reimbursement Process: Japan
Figure 15.34 Healthcare Insurance Coverage in Japan: Percentage Distribution by Type of Coverage
Figure 15.35 New Medical Devices Reimbursement Process: Japan
Figure 15.36 Medical Devices Review / Approval Process: New Zealand
Figure 15.37 Healthcare Insurance Coverage in New Zealand: Percentage Distribution by Type of Coverage
Figure 15.38 Medical Devices Review / Approval Process: Singapore
Figure 15.39 Medical Devices Review / Approval Process: South Korea
Figure 15.40 Healthcare Insurance Coverage in South Korea: Percentage Distribution by Type of Coverage
Figure 15.41 Medical Devices Review / Approval Process: South Africa
Figure 15.42 Medical Devices Review / Approval Process: Taiwan
Figure 15.43 Healthcare Insurance Coverage in Taiwan: Percentage Distribution by Type of Coverage
Figure 15.44 Medical Devices Review / Approval Process: Thailand
Figure 15.45 Heat Map Analysis: Comparison of Regional Regulatory Control for Medical Devices
Figure 15.46 Regulatory Control for Medical Devices: Regional Analysis by Device Risk Category
Figure 16.1 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, 2020-2030 (USD Million)
Figure 16.2 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device, 2020-2030 (USD Million)
Figure 16.3 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability, 2020-2030 (USD Million)
Figure 16.4 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area, 2020-2030 (USD Million)
Figure 16.5 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, 2020-2030 (USD Million)
Figure 16.6 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Type of Device, 2020-2030 (USD Million)
Figure 16.7 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Usability, 2020-2030 (USD Million)
Figure 16.8 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Therapeutic Area, 2020-2030 (USD Million)
Figure 16.9 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, 2020-2030 (USD Million)
Figure 16.10 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Type of Device, 2020-2030 (USD Million)
Figure 16.11 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Usability, 2020-2030 (USD Million)
Figure 16.12 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Therapeutic Area, 2020-2030 (USD Million)
Figure 16.13 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific, 2020-2030 (USD Million)
Figure 16.14 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Type of Device, 2020-2030 (USD Million)
Figure 16.15 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Usability, 2020-2030 (USD Million)
Figure 16.16 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Therapeutic Area, 2020-2030 (USD Million)
Figure 16.17 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, 2020-2030 (Units, Million)
Figure 16.18 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device, 2020-2030 (Units, Million)
Figure 16.19 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability, 2020-2030 (Units, Million)
Figure 16.20 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area, 2020-2030 (Units, Million)
Figure 16.21 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, 2020-2030 (Units, Million)
Figure 16.22 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Type of Device, 2020-2030 (Units, Million)
Figure 16.23 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Usability, 2020-2030 (Units, Million)
Figure 16.24 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Therapeutic Area, 2020-2030 (Units, Million)
Figure 16.25 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, 2020-2030 (Units, Million)
Figure 16.26 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Type of Device, 2020-2030 (Units, Million)
Figure 16.27 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Usability, 2020-2030 (Units, Million)
Figure 16.28 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Therapeutic Area, 2020-2030 (Units, Million)
Figure 16.29 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific, 2020-2030 (Units, Million)
Figure 16.30 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Type of Device, 2020-2030 (Units, Million)
Figure 16.31 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Usability, 2020-2030 (Units, Million)
Figure 16.32 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Therapeutic Area, 2020-2030 (Units, Million)
Figure 16.33 Global Large Volume Wearable Injectors Market for Insulin, 2020-2030 (USD Million)
Figure 16.34 Global Large Volume Wearable Injectors Market for Insulin: Distribution by Type of Device, 2020-2030 (USD Million)
Figure 16.35 Global Large Volume Wearable Injectors Market for Insulin: Distribution by Usability, 2020-2030 (USD Million)
Figure 16.36 Large Volume Wearable Injectors Market for Insulin in North America, 2020-2030 (USD Million)
Figure 16.37 Large Volume Wearable Injectors Market for Insulin in North America: Distribution by Type of Device, 2020-2030 (USD Million)
Figure 16.38 Large Volume Wearable Injectors Market for Insulin in North America: Distribution by Usability, 2020-2030 (USD Million)
Figure 16.39 Large Volume Wearable Injectors Market for Insulin in Europe, 2020-2030 (USD Million)
Figure 16.40 Large Volume Wearable Injectors Market for Insulin in Europe: Distribution by Type of Device, 2020-2030 (USD Million)
Figure 16.41 Large Volume Wearable Injectors Market for Insulin in Europe: Distribution by Usability, 2020-2030 (USD Million)
Figure 16.42 Large Volume Wearable Injectors Market for Insulin in Asia Pacific, 2020-2030 (USD Million)
Figure 16.43 Large Volume Wearable Injectors Market for Insulin in Asia Pacific: Distribution by Type of Device, 2020-2030 (USD Million)
Figure 16.44 Large Volume Wearable Injectors Market for Insulin in Asia Pacific: Distribution by Usability, 2020-2030 (USD Million)
Figure 16.45 Global Large Volume Wearable Injectors Market for Insulin, 2020-2030 (Units, Million)
Figure 16.46 Global Large Volume Wearable Injectors Market for Insulin: Distribution by Type of Device, 2020-2030 (Units, Million)
Figure 16.47 Global Large Volume Wearable Injectors Market for Insulin: Distribution by Usability, 2020-2030 (Units, Million)
Figure 16.48 Large Volume Wearable Injectors Market for Insulin in North America, 2020-2030 (Units, Million)
Figure 16.49 Large Volume Wearable Injectors Market for Insulin in North America: Distribution by Type of Device, 2020-2030 (Units, Million)
Figure 16.50 Large Volume Wearable Injectors Market for Insulin in North America: Distribution by Usability, 2020-2030 (Units, Million)
Figure 16.51 Large Volume Wearable Injectors Market for Insulin in Europe, 2020-2030 (Units, Million)
Figure 16.52 Large Volume Wearable Injectors Market for Insulin in Europe: Distribution by Type of Device, 2020-2030 (Units, Million)
Figure 16.53 Large Volume Wearable Injectors Market for Insulin in Europe: Distribution by Usability, 2020-2030 (Units, Million)
Figure 16.54 Large Volume Wearable Injectors Market for Insulin in Asia Pacific, 2020-2030 (Units, Million)
Figure 16.55 Large Volume Wearable Injectors Market for Insulin in Asia Pacific: Distribution by Type of Device, 2020-2030 (Units, Million)
Figure 16.56 Large Volume Wearable Injectors Market for Insulin in Asia Pacific: Distribution by Usability, 2020-2030 (Units, Million)

List Of Tables

Table 3.1 List of Prefilled Syringes
Table 3.2 List of Pen-Injector Systems
Table 3.3 List of Autoinjector Systems
Table 3.4 List of Needle-Free Injectors
Table 4.1 Large Volume Wearable Injectors for Non-Insulin Drugs: Information on Development Status and Device Features
Table 4.2 Large Volume Wearable Injectors for Non-Insulin Drugs: Information on Administration Related Parameters
Table 4.3 Large Volume Drug Device Combinations for Non-Insulin Drugs: Information on Development Status and Device Features
Table 4.4 Large Volume Drug Device Combinations for Non-Insulin Drugs: Information on Administration Related Parameters
Table 4.5 Large Volume Wearable Injectors for Non-Insulin Drugs: Information on Developers (Both Devices and Drug Device Combinations)
Table 4.6 Large Volume Wearable Injectors for Insulin: Information on Development Status and Device Features
Table 4.7 Large Volume Wearable Injectors for Insulin: Information on Device Monitoring and Connectivity Features
Table 4.8 Large Volume Wearable Injectors for Insulin: Information on Developers
Table 6.1 Large Volume Wearable Injectors for Non-Insulin Drugs: List of Players Profiled
Table 6.2 Large Volume Wearable Injectors for Insulin: List of Players Profiled
Table 6.3 Becton Dickinson: Medical Devices Portfolio
Table 6.4 Becton Dickinson: Recent Developments and Future Outlook
Table 6.5 Bespak: Recent Developments and Future Outlook
Table 6.6 Enable Injections: Recent Developments and Future Outlook
Table 6.7 Insulet: Recent Developments and Future Outlook
Table 6.8 Roche: Recent Developments and Future Outlook
Table 6.9 Sensile Medical: Medical Devices Portfolio
Table 6.10 Sensile Medical: Recent Developments and Future Outlook
Table 6.11 Sonceboz: Medical Devices Portfolio
Table 6.12 Sonceboz: Recent Developments and Future Outlook
Table 6.13 SteadyMed Therapeutics: Medical Devices Portfolio
Table 6.14 SteadyMed Therapeutics: Recent Developments and Future Outlook
Table 6.15 Weibel CDS: Medical Devices Portfolio
Table 6.16 Weibel CDS: Recent Developments and Future Outlook
Table 6.17 West Pharmaceutical Services: Recent Developments and Future Outlook
Table 6.18 CeQur: Recent Developments and Future Outlook
Table 6.19 Debiotech: Medical Devices Portfolio
Table 6.20 Debiotech: Recent Developments and Future Outlook
Table 6.21 Eli Lilly: Recent Developments and Future Outlook
Table 6.22 Medtronic: Recent Developments and Future Outlook
Table 6.23 SOOIL Development: Recent Developments and Future Outlook
Table 6.24 Tandem Diabetes Care: Features of slim X2 Insulin Pump
Table 6.25 Tandem Diabetes Care: Technology Portfolio
Table 6.26 Tandem Diabetes Care: Recent Developments and Future Outlook
Table 7.1 Large Volume Drug Device Combination: Apomorphine / D-mine® Pump
Table 7.2 Large Volume Drug Device Combination: Apomorphine / ND0701
Table 7.3 Large Volume Drug Device Combination: Bupivacaine / SMT-301
Table 7.4 Large Volume Drug Device Combination: Ceftriaxone / sc2Wear® Infusor
Table 7.5 Large Volume Drug Device Combination: Furosemide / 3 mL Micropump
Table 7.6 Large Volume Drug Device Combination: Furosemide / FUROSCIX® On-body Infusor
Table 7.7 Large Volume Drug Device Combination: Herceptin® SC / Roche’s Injector Device
Table 7.8 Large Volume Drug Device Combination: Ketorolac / SMT-201
Table 7.9 Large Volume Drug Device Combination: Levadopa and Carbidopa / ND0612 and ND0901
Table 7.10 Large Volume Drug Device Combination: Lutrepulse / The LUTREPULSE® System
Table 7.11 Large Volume Drug Device Combination: Repatha® / Pushtronex® System
Table 7.12 Large Volume Drug Device Combination: Treprostinil / Trevyent®
Table 8.1 Large Volume Wearable Injectors: List of Partnerships and Collaborations
Table 10.1 Patent Analysis: CPC Symbol Definitions
Table 10.2 Patent Analysis: List of Top CPC Symbols
Table 10.3 Patent Analysis: List of Most Popular CPC Symbols
Table 10.4 Patent Analysis: Summary of Benchmarking Analysis
Table 10.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 10.6 Patent Analysis: List of Leading Patents (by Highest Relative Valuation)
Table 11.1 Marketed Molecules: Most Likely Candidates for Delivery via Large Volume Wearable Injectors
Table 11.2 Marketed Molecules: Likely Candidates for Delivery via Large Volume Wearable Injectors
Table 11.3 Marketed Molecules: Less Likely Candidates for Delivery via Large Volume Wearable Injectors
Table 11.4 Marketed Molecules: Unlikely Candidates for Delivery via Large Volume Wearable Injectors
Table 11.5 Clinical Drug Candidates (Biologics): Most Likely Candidates for Delivery via Large Volume Wearable Injectors
Table 11.6 Clinical Drug Candidates (Biologics): Likely Candidates for Delivery via Large Volume Wearable Injectors
Table 11.7 Clinical Drug Candidates (Biologics): Less Likely Candidates for Delivery via Large Volume Wearable Injectors
Table 11.8 Clinical Drug Candidates (Biologics): Unlikely Candidates for Delivery via Large Volume Wearable Injectors
Table 11.9 Clinical Drug Candidates (Small Molecules): Most Likely Candidates for Delivery via Large Volume Wearable Injectors
Table 11.10 Clinical Drug Candidates (Small Molecules): Likely Candidates for Delivery via Large Volume Wearable Injectors
Table 11.11 Clinical Drug Candidates (Small Molecules): Less Likely Candidates for Delivery via Large Volume Wearable Injectors
Table 11.12 Clinical Drug Candidates (Small Molecules): Unlikely Candidates for Delivery via Large Volume Wearable Injectors
Table 14.1 List of Contract Manufacturing Organizations
Table 15.1 General Guidelines for Market Authorization and Reimbursement for Medical Devices
Table 15.2 Device Classification: US
Table 15.3 Device Classification: Canada
Table 15.4 Data Requirements and Characteristics of Province-wide HTA Processes in Canada
Table 15.5 Device Classification: Mexico
Table 15.6 Device Classification: Europe
Table 15.7 List of CE Directives in Europe
Table 15.8 Conformity Assessment Modules in Europe
Table 15.9 Device Classification: Australia
Table 15.10 Medical Devices Reimbursement and Pricing Approval Process: Australia
Table 15.11 Device Classification: Brazil
Table 15.12 Device Classification: China
Table 15.13 Device Classification: India
Table 15.14 Device Classification: Japan
Table 15.15 Medical Devices Reimbursement Categories
Table 15.16 Device Classification: Medsafe
Table 15.17 Device Classification: Singapore
Table 15.18 Device Classification: South Korea
Table 15.19 Device Classification: South Africa
Table 15.20 Device Classification: Thailand
Table 15.21 Medical Devices Regulatory Landscape Summary
Table 15.22 Medical Devices Reimbursement Landscape Summary
Table 16.1 Large Volume Drug Device Combinations: List of Approved / Under Development Products
Table 16.2 Large Volume Wearable Injectors for Insulin Delivery: Annual Treatment Cost Information
Table 18.1 Company Snapshot: Medipacs
Table 18.2 Company Snapshot: Enable Injections
Table 18.3 Company Snapshot: Subcuject
Table 18.4 Company Snapshot: scPharmaceuticals
Table 18.5 Company Snapshot: Elcam Medical
Table 18.6 Company Snapshot: West Pharmaceutical Services
Table 18.7 Company Snapshot: Sorrel Medical
Table 19.1 Large Volume Wearable Injectors: Overall Market Landscape
Table 19.2 Large Volume Wearable Injectors for Non-Insulin Drugs: Analysis by Stage of Development
Table 19.3 Large Volume Wearable Injectors for Non-Insulin Drugs: Analysis by Type of Device
Table 19.4 Large Volume Wearable Injectors for Non-Insulin Drugs: Analysis by Type of Dose
Table 19.5 Large Volume Wearable Injectors for Non-Insulin Drugs: Analysis by Route of Administration
Table 19.6 Large Volume Wearable Injectors for Non-Insulin Drugs: Analysis by Mode of Injection
Table 19.7 Large Volume Wearable Injectors for Non-Insulin Drugs: Analysis by Volume / Storage Capacity
Table 19.8 Large Volume Wearable Injectors for Non-Insulin Drugs: Analysis by Actuation Mechanism
Table 19.9 Large Volume Wearable Injectors for Non-Insulin Drugs: Analysis by Usability
Table 19.10 Large Volume Wearable Injectors for Non-Insulin Drugs: Analysis by Availability of Prefilled Drug Reservoir
Table 19.11 Large Volume Wearable Injectors for Non-Insulin Drugs: Analysis by Connectivity
Table 19.12 Large Volume Drug Device Combinations: Analysis by Stage of Development
Table 19.13 Large Volume Drug Device Combinations: Analysis by Type of Device
Table 19.14 Large Volume Drug Device Combinations: Analysis by Drug Compatibility
Table 19.15 Large Volume Drug Device Combinations: Analysis by Type of Dose
Table 19.16 Large Volume Drug Device Combinations: Analysis by Route of Administration
Table 19.17 Large Volume Drug Device Combinations: Analysis by Mode of Injection
Table 19.18 Large Volume Drug Device Combinations: Analysis by Therapeutic Area
Table 19.19 Large Volume Drug Device Combinations: Analysis by Volume / Storage Capacity
Table 19.20 Large Volume Drug Device Combinations: Analysis by Usability
Table 19.21 Large Volume Wearable Injectors for Non-Insulin Drugs: Analysis of Developers by Year of Establishment (Devices and Drug Device Combinations)
Table 19.22 Large Volume Wearable Injectors for Non-Insulin Drugs: Analysis of Developers by Size (Devices and Drug Device Combinations)
Table 19.23 Large Volume Wearable Injectors for Non-Insulin Drugs: Analysis of Developers by Geography (Devices and Drug Device Combinations)
Table 19.24 Large Volume Wearable Injectors for Insulin: Analysis by Stage of Development
Table 19.25 Large Volume Wearable Injectors for Insulin: Analysis by Type of Device
Table 19.26 Large Volume Wearable Injectors for Insulin: Analysis by Volume / Storage Capacity
Table 19.27 Large Volume Wearable Injectors for Insulin: Analysis by Usability
Table 19.28 Large Volume Wearable Injectors for Insulin: Analysis by Availability of Prefilled Insulin Cartridges
Table 19.29 Large Volume Wearable Injectors for Insulin: Analysis by Availability of CGM / BGM System
Table 19.30 Large Volume Wearable Injectors for Insulin: Analysis by Availability of Automated Insulin Delivery (AID) Feature
Table 19.31 Large Volume Wearable Injectors for Insulin: Analysis by Availability of Connectivity
Table 19.32 Large Volume Wearable Injectors for Insulin: Analysis of Developers by Year of Establishment
Table 19.33 Large Volume Wearable Injectors for Insulin: Analysis of Developers by Size
Table 19.34 Large Volume Wearable Injectors for Insulin: Analysis of Developers by Geography
Table 19.35 Patent Analysis: Distribution by Type of Patent
Table 19.36 Patent Analysis: Distribution by Publication Year
Table 19.37 Patent Analysis: Distribution by Issuing Authority / Patent Offices Involved
Table 19.38 Patent Analysis: Distribution by Type of Organization
Table 19.39 Patent Analysis: Leading Industry Players
Table 19.40 Patent Analysis: Leading Non-Industry Players
Table 19.41 Patent Analysis: Leading Individual Assignees
Table 19.42 Patent Analysis: Distribution of Patents by Age
Table 19.43 Social Media Analysis: Most Influential Authors Related to Large Volume Wearable Injectors on Twitter
Table 19.44 Social Media Analysis: Comparison of Most Popular Players
Table 19.45 Clinical Trials: Analysis by Trial Registration Year
Table 19.46 Clinical Trials: Analysis by Trial Phase
Table 19.47 Clinical Trials: Analysis by Trial Status
Table 19.48 Clinical Trials: Analysis by Study Design
Table 19.49 Clinical Trials: Analysis by Target Therapeutic Area / Indication
Table 19.50 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 19.51 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 19.52 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 19.53 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 19.54 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 19.55 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Type of Device, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 19.56 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Usability, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 19.57 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 19.58 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 19.59 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Type of Device, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 19.60 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Usability, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 19.61 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 19.62 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific and Rest of the World, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 19.63 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Type of Device, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 19.64 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific and Rest of the World: Distribution by Usability, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 19.65 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific and Rest of the World: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 19.66 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, Conservative, Base and Optimistic Scenarios, 2020-2030 (Units, Million)
Table 19.67 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device, Conservative, Base and Optimistic Scenarios, 2020-2030 (Units, Million)
Table 19.68 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability, Conservative, Base and Optimistic Scenarios, 2020-2030 (Units, Million)
Table 19.69 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenarios, 2020-2030 (Units, Million)
Table 19.70 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, Conservative, Base and Optimistic Scenarios, 2020-2030 (Units, Million
Table 19.71 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Type of Device, Conservative, Base and Optimistic Scenarios, 2020-2030 (Units, Million)
Table 19.72 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Usability, Conservative, Base and Optimistic Scenarios, 2020-2030 (Units, Million)
Table 19.73 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenarios, 2020-2030 (Units, Million)
Table 19.74 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, Conservative, Base and Optimistic Scenarios, 2020-2030 (Units, Million)
Table 19.75 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Type of Device, Conservative, Base and Optimistic Scenarios, 2020-2030 (Units, Million)
Table 19.76 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Usability, Conservative, Base and Optimistic Scenarios, 2020-2030 (Units, Million)
Table 19.77 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenarios, 2020-2030 (Units, Million)
Table 19.78 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific, Conservative, Base and Optimistic Scenarios, 2020-2030 (Units, Million)
Table 19.79 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Type of Device, Conservative, Base and Optimistic Scenarios, 2020-2030 (Units, Million)
Table 19.80 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Usability, Conservative, Base and Optimistic Scenarios, 2020-2030 (Units, Million)
Table 19.81 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenarios, 2020-2030 (Units, Million)
Table 19.82 Global Large Volume Wearable Injectors Market for Insulin, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 19.83 Global Large Volume Wearable Injectors Market for Insulin: Distribution by Type of Device, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 19.84 Global Large Volume Wearable Injectors Market for Insulin: Distribution by Usability, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 19.85 Large Volume Wearable Injectors Market for Insulin in North America, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 19.86 Large Volume Wearable Injectors Market for Insulin in North America: Distribution by Type of Device, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 19.87 Large Volume Wearable Injectors Market for Insulin in North America: Distribution by Usability, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 19.88 Large Volume Wearable Injectors Market for Insulin in Europe, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 19.89 Large Volume Wearable Injectors Market for Insulin in Europe: Distribution by Type of Device, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 19.90 Large Volume Wearable Injectors Market for Insulin in Europe: Distribution by Usability, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 19.91 Large Volume Wearable Injectors Market for Insulin in Asia Pacific, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 19.92 Large Volume Wearable Injectors Market for Insulin in Asia Pacific: Distribution by Type of Device, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 19.93 Large Volume Wearable Injectors Market for Insulin in Asia Pacific: Distribution by Usability, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 19.94 Global Large Volume Wearable Injectors Market for Insulin, Conservative, Base and Optimistic Scenarios, 2020-2030 (Units, Million)
Table 19.95 Global Large Volume Wearable Injectors Market for Insulin: Distribution by Type of Device, Conservative, Base and Optimistic Scenarios, 2020-2030 (Units, Million)
Table 19.96 Global Large Volume Wearable Injectors Market for Insulin: Distribution by Usability, Conservative, Base and Optimistic Scenarios, 2020-2030 (Units, Million)
Table 19.97 Large Volume Wearable Injectors Market for Insulin in North America, Conservative, Base and Optimistic Scenarios, 2020-2030 (Units, Million)
Table 19.98 Large Volume Wearable Injectors Market for Insulin in North America: Distribution by Type of Device, Conservative, Base and Optimistic Scenarios, 2020-2030 (Units Million)
Table 19.99 Large Volume Wearable Injectors Market for Insulin in North America: Distribution by Usability, Conservative, Base and Optimistic Scenarios, 2020-2030 (Units, Million)
Table 19.100 Large Volume Wearable Injectors Market for Insulin in Europe, Conservative, Base and Optimistic Scenarios, 2020-2030 (Units, Million)
Table 19.101 Large Volume Wearable Injectors Market for Insulin in Europe: Distribution by Type of Device, Conservative, Base and Optimistic Scenarios, 2020-2030 (Units, Million)
Table 19.102 Large Volume Wearable Injectors Market for Insulin in Europe: Distribution by Usability, Conservative, Base and Optimistic Scenarios, 2020-2030 (Units, Million)
Table 19.103 Large Volume Wearable Injectors Market for Insulin in Asia Pacific, Conservative, Base and Optimistic Scenarios, 2020-2030 (Units, Million)
Table 19.104 Large Volume Wearable Injectors Market for Insulin in Asia Pacific: Distribution by Type of Device, Conservative, Base and Optimistic Scenarios, 2020-2030 (Units, Million)
Table 19.105 Large Volume Wearable Injectors Market for Insulin in Asia Pacific: Distribution by Usability, Conservative, Base and Optimistic Scenarios, 2020-2030 (Units, Million)

Listed Companies

  1. 3M
  2. Abbott
  3. AbbVie
  4. AbGenomics
  5. Ablynx
  6. Acceleron Pharma
  7. Accenture
  8. Actavis Pharma
  9. ADC Therapeutics
  10. Adrenomed
  11. Aduro Biotech
  12. Advaxis
  13. Aeglea BioTherapeutics
  14. Aetna
  15. Affibody
  16. Affimed
  17. Agenus
  18. AgonOx
  19. Akesobio Australia
  20. Alder BioPharmaceuticals
  21. Alector
  22. Alexion Pharmaceuticals
  23. Alkahest
  24. Alkermes
  25. Allakos
  26. Allergan
  27. Alnylam Pharmaceuticals
  28. Allozyne
  29. AlphaCore Pharma
  30. Altor BioScience
  31. Ambrx
  32. amcure
  33. Amgen
  34. Amicus Therapeutics
  35. Amphivena Therapeutics
  36. Amplyx Pharmaceuticals
  37. Angiochem 
  38. Antares Pharma
  39. Antaros Medical
  40. Apellis Pharmaceuticals
  41. Aprea Therapeutics
  42. Aptevo Therapeutics
  43. argenx 
  44. Argos Therapeutics
  45. ArmaGen
  46. ARMO BioSciences
  47. Aronora
  48. Asante Solutions
  49. Ascensia Diabetes Care
  50. Asklepion Pharmaceuticals
  51. Astorg Partners
  52. Astellas Pharma
  53. AstraZeneca
  54. Atridia
  55. Australasian Medical & Scientific
  56. Axon Neuroscience
  57. Baril 
  58. Basilea Pharmaceutica
  59. Bastian Solutions
  60. Battelle
  61. Baxter International
  62. Bayer
  63. Bayhill Therapeutics
  64. Becton Dickinson
  65. BeiGene
  66. Beijing Dongfang Biotech
  67. Bespak
  68. Beta Bionics
  69. Bigfoot Biomedical 
  70. BioArctic
  71. BIOCAD
  72. Biogen
  73. BioIntegrator
  74. Bioject Medical Technologies
  75. BioMarin Pharmaceutical
  76. Bioniz Therapeutics
  77. BioNTech
  78. Bio-Path Holdings
  79. Biotest Pharmaceuticals
  80. Bio-Thera Solutions
  81. Boehringer Ingelheim
  82. Boston Pharmaceuticals
  83. Bristol Myers Squibb
  84. Bühler Motor 
  85. Calando Pharmaceuticals
  86. Calibra Medical
  87. Cam Med
  88. CANbridge Life Sciences
  89. Cancer Advances
  90. Cara Therapeutics
  91. Cardiome Pharma
  92. Care Innovations
  93.     Catalyst Biosciences
  94. Celgene
  95. Celldex Therapeutics
  96. CEL-SCI
  97. CeQur
  98. Chimerix
  99. CHO Pharma
  100. Chugai Pharmaceutical
  101. Cleveland BioLabs
  102. Conjupro Biotherapeutics
  103. Consort Medical
  104. ContraFect
  105. ConvaTec
  106. Cordant Group
  107. Cour Pharmaceutical Development
  108. CSL Behring
  109. CStone Pharmaceuticals
  110. CureTech
  111. CytoDyn
  112. Daikyo Seiko
  113. Datwyler
  114. Debiotech
  115. DEKA
  116. Dekkun
  117. Delta-Fly Pharma
  118. Dendreon
  119. Dexcom
  120. Diabeloop
  121. DiaMedica Therapeutics
  122. Diamyd Medical
  123. DreaMed Diabetes
  124. Duke University
  125. E3D Elcam Drug Delivery Devices
  126. European Connected Health Alliance (ECHAlliance)
  127. EG-GILERO
  128. Eisai
  129. Eitan Group
  130. Eli Lilly
  131. Elusys Therapeutics
  132. EMD Serono
  133. Emergent BioSolutions
  134. Enable Injections
  135. Endocyte
  136. EnGeneIC 
  137. EOFlow
  138. EpicentRx
  139. Eris Lifesciences
  140. EVER Pharma
  141. Evidation Health
  142. F2G 
  143. Fabrico
  144. Ferring Pharmaceuticals
  145. FibroGen
  146. Fitbit
  147. Five Prime Therapeutics
  148. Flex Pharma
  149. Flex
  150. Flowonix Medical
  151. Fresenius Medical Care
  152. Galaxy Biotech
  153. Galena Biopharma
  154. FedEx Supply Chain 
  155. Genentech
  156. GENERON
  157. GeneScience Pharmaceuticals
  158. Genexine
  159. Genzyme
  160. Georgia Institute of Technology
  161. Gerresheimer
  162. Gilead Sciences
  163. GlaxoSmithKline
  164. Glenmark Pharmaceuticals
  165. Gliknik
  166. Glooko
  167. Guangzhou Cellprotek Pharmaceutical
  168. HAL Allergy
  169. Halozyme Therapeutics
  170. Hanmi Pharmaceutical
  171. Harvard Pilgrim Health Care
  172. Haselmeier
  173. HealthPrize Technologies
  174. Helsinn Healthcare
  175. Hemispherx Biopharm
  176. Hoffmann-La Roche
  177. Huabo Biopharm
  178. IBM Watson
  179. International Diabetes Federation
  180. ImClone Systems
  181. Immatics Biotechnologies
  182. Immune Response BioPharma
  183. ImmunGene
  184. Immunocore
  185. ImmunoFrontier
  186. ImmunoGen
  187. Immunomedics
  188. Immunotope
  189. Immunovaccine
  190. Implicit Bioscience
  191. Incuron
  192. Incyte
  193. Innate Pharma
  194. Innovent Biologics
  195. Inovio Pharmaceuticals
  196. Insulet
  197. iNtRON Biotechnology
  198. IO Biotech
  199. Ionis Pharmaceuticals
  200. Ipsen
  201. iSense CGM
  202. ISU ABXIS
  203. Janssen
  204. Jerini
  205. JHL Biotech
  206. Jiangsu Hengrui Medicine
  207. Jiangsu T-Mab Biopharma
  208. Johnson & Johnson
  209. Jounce Therapeutics
  210. Juvenile Diabetes Research Foundation
  211. KaloBios Pharmaceuticals
  212. Kiniksa Pharmaceuticals
  213. Kissei Pharmaceutical
  214. Klue
  215. Kura Oncology
  216. Kyowa Hakko Kirin
  217. Labrys Biologics
  218. LEO Pharma
  219. Levicept
  220. Life Science Pharmaceuticals
  221. MabVax Therapeutics
  222. MacroGenics
  223. Massachusetts Institute of Technology
  224. MedImmune
  225. Medimop Medical Projects
  226. Medipacs
  227. Medtronic
  228. Medtrum Technologies
  229. Menarini Diagnostics
  230. Menarini Group
  231. Merck
  232. Merck Sharp & Dohme
  233. Mercy Technology Services
  234. Mereo BioPharma
  235. Merrimack Pharmaceuticals
  236. Mersana Therapeutics
  237. Merus
  238. Merz Pharma
  239. Millennium Pharmaceuticals
  240. MiNA Therapeutics
  241. miRagen Therapeutics
  242. Mitsubishi Tanabe Pharma
  243. Mode AGC (Automated Glucose Control)
  244. Moderna Therapeutics
  245. Molecular Partners
  246. Molecular Templates
  247. MolMed
  248. Montagu Private Equity
  249. MorphoSys
  250. Morphotek
  251. Movi
  252. MTD Micro Molding
  253. mySugr
  254. NanoPass Technologies
  255. NantBioScience
  256. Naurex
  257. Navidea Biopharmaceuticals
  258. Nemera
  259. Neogenix Oncology
  260. Neon Therapeutics
  261. NeuroDerm
  262. New Zealand Medical & Scientific
  263. Noble
  264. Nordic Bioscience
  265. Nordic Infucare
  266. Northern Biologics
  267. Novartis Pharmaceuticals
  268. Novimmune
  269. NOVO Engineering
  270. Novo Nordisk
  271. OBI Pharma
  272. Octapharma
  273. Omeros
  274. Oncology Venture
  275. OncoMed Pharmaceuticals
  276. OncoPep
  277. Oncopeptides
  278. Oncternal Therapeutics
  279. Oncurious
  280. Opthea
  281. Optimer Pharmaceuticals
  282. OSE Immunotherapeutics
  283. Otsuka Pharmaceutical
  284. Owen Mumford
  285. Paion UK
  286. Panacea Biotec
  287. PercuSense
  288. Pfizer
  289. PharmaJet
  290. PharmaMar
  291. PharmaSens
  292. PhaseBio Pharmaceuticals
  293. Phillips-Medisize
  294. Philogen
  295. Phosplatin Therapeutics
  296. Pierre Fabre
  297. Pique Therapeutics
  298. Polaris Group
  299. Polyphor
  300. Prescient Therapeutics
  301. Prestige BioPharma
  302. Promedior
  303. Prometheus Laboratories
  304. Protalix Biotherapeutics
  305. Proven Process Medical Devices 
  306. Pulmonary Hypertension Association
  307. Qualcomm
  308. Quest PharmaTech
  309. Quintessence Biosciences
  310. Ratio Drug Delivery
  311. RAUMEDIC
  312. Recro Pharma
  313. Recipharm
  314. Regeneron Pharmaceuticals
  315. REM Systems
  316. REMD Biotherapeutics
  317. Resolve Therapeutics
  318. rEVO Biologics
  319. Rhythm Pharmaceuticals
  320. Roche
  321. Roehr pharmaceuticals
  322. R-Pharm
  323. Rubin Medical
  324. RxActuator
  325. Sagentia
  326. Samsung Bioepis
  327. Sandoz
  328. Sanofi
  329. Santarus
  330. Saol Therapeutics
  331. Savient Pharmaceuticals
  332. scPharmaceuticals
  333. Seattle Genetics
  334. Selecta Biosciences
  335. Selexys Pharmaceuticals
  336. Sensile Medical
  337. Serina Therapeutics
  338. SFC Fluidics
  339. Shire
  340. SHL Medical
  341. Singularity University
  342. SMC Global
  343. Smiths Medical
  344. Sonceboz
  345. SOOIL Development
  346. SPARK Strategic Ideas
  347. SQ Innovation
  348. SteadyMed Therapeutics
  349. Stealth BioTherapeutics
  350. Stemline Therapeutics
  351. Stevanato Group
  352. Subcuject
  353. Sumitomo Dainippon Pharma
  354. Sunovion Pharmaceuticals
  355. Swissfillon
  356. SymBio Pharmaceuticals
  357. Symphogen
  358. Synectics
  359. Synermore Biologics
  360. Syntimmune
  361. Syros Pharmaceuticals
  362. TaiMed Biologics
  363. Taiwan Liposome Company
  364. Takeda Pharmaceutical
  365. Tandem Diabetes Care
  366. Tanvex BioPharma
  367. Tarveda Therapeutics
  368. Teva Pharmaceutical
  369. TG Therapeutics
  370. Theras Lifetech
  371. Tidepool
  372. Tolero Pharmaceuticals
  373. TRACON Pharmaceuticals
  374. Translational Sciences
  375. Turnstone Biologics
  376. Tyndall National Institute
  377. TypeZero Technologies
  378. Union Chimique Belge (UCB)
  379. United BioPharma
  380. United Therapeutics
  381. University of Arizona
  382. University of Bern
  383. University of Colorado
  384. University of Hertfordshire
  385. University of Virginia
  386. Vaccinex
  387. Vaccinogen
  388. Valtronic
  389. vasopharm BIOTECH
  390. Verily Life Sciences
  391. Vetter Pharma
  392. ViCentra
  393. ViiV Healthcare
  394. Visterra
  395. Vivozon
  396. Weibel CDS
  397. West Pharmaceutical Services
  398. Wockhardt
  399. XBiotech
  400. Xencor
  401. XOMA
  402. Ypsomed
  403. Zafgen
  404. Zealand Pharma
  405. Zollner
  406. Zuellig Pharma

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 4,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com